Global Primary Hyperoxaluria Drug Market Report (2026–2036)
Market Overview
The global primary hyperoxaluria drug market is projected to grow steadily during 2026–2036, driven by rising prevalence of rare genetic kidney disorders, increasing demand for novel RNAi-based therapies, and expanding healthcare infrastructure worldwide. Growth is further supported by advancements in gene therapy, small interfering RNA (siRNA) drugs, and supportive treatments aimed at reducing oxalate levels and preventing kidney damage.
Key Players
In addition to the listed manufacturers, the following companies are also significant participants in the global primary hyperoxaluria drug market:
- Pfizer Inc. (US)
- Novartis AG (Switzerland)
- Roche Holding AG (Switzerland)
- Eli Lilly and Company (US)
- Sanofi S.A. (France)
- Takeda Pharmaceutical Company Ltd. (Japan)
- Bristol Myers Squibb (US)
- Regeneron Pharmaceuticals, Inc. (US)
- Ultragenyx Pharmaceutical Inc. (US)
- Silence Therapeutics Plc (UK)
These players compete on innovation, clinical trial pipelines, regulatory approvals, and global distribution networks.
Segments Analysis
By Product Type
- ALLN-230 – Investigational therapy targeting oxalate metabolism.
- DCR-PHXC – RNAi-based therapy under development.
- ALN-GO1 – Alnylam’s siRNA therapy for primary hyperoxaluria.
- Others – Includes pipeline drugs, gene therapies, and supportive treatments.
By Application
- Hospitals – Primary centers for advanced rare disease treatment and clinical trials.
- Clinics – Outpatient facilities providing supportive therapies.
- Others – Includes academic research institutions and specialty nephrology centers.
Regional Analysis
- North America – Largest market, led by the U.S.; strong clinical trial activity and advanced rare disease infrastructure.
- Europe – Significant adoption in Germany, UK, and France; focus on EMA regulatory pathways and orphan drug incentives.
- Asia-Pacific – Fastest-growing region; China, India, and Japan drive growth due to rising healthcare investments and rare disease awareness.
- South America – Brazil and Argentina show increasing adoption in urban hospitals and specialty clinics.
- Middle East & Africa – Emerging demand in Saudi Arabia, Turkey, and South Africa, supported by expanding healthcare infrastructure.
Porter’s Five Forces
- Threat of New Entrants – Moderate; requires high R&D investment and regulatory approvals.
- Bargaining Power of Suppliers – Moderate; specialized biotech inputs and RNAi expertise influence pricing.
- Bargaining Power of Buyers – High; hospitals and rare disease centers demand cost-effective and innovative therapies.
- Threat of Substitutes – Moderate; alternative supportive therapies and dialysis compete.
- Industry Rivalry – High; strong competition among global pharmaceutical and biotech firms.
SWOT Analysis
Strengths
- Strong pipeline of investigational RNAi and gene therapies.
- Broad applications across hospitals and clinics.
- Growing investment in rare disease research.
Weaknesses
- High R&D and clinical trial costs.
- Regulatory challenges in orphan drug approvals.
- Limited awareness in low-income regions.
Opportunities
- Rising demand for targeted RNAi therapies.
- Expansion into emerging markets with unmet medical needs.
- Growth in gene therapy and personalized medicine.
Threats
- Competition from alternative rare disease therapies.
- Patent expirations leading to generic competition.
- Price sensitivity in cost-conscious healthcare systems.
Trend Analysis
- Increasing adoption of RNAi-based therapies for rare kidney disorders.
- Rising focus on gene therapy approaches for rare diseases.
- Growth in clinical trials across Asia-Pacific and Latin America.
- Expansion of orphan drug designations and regulatory incentives.
- Development of combination therapies for improved outcomes.
Drivers & Challenges
Drivers
- Rising prevalence of primary hyperoxaluria globally.
- Expanding demand for advanced therapies and personalized medicine.
- Growing investments in rare disease R&D.
Challenges
- High costs of drug development and long timelines.
- Regulatory hurdles across multiple regions.
- Competition from established supportive therapies.
Value Chain Analysis
- Raw Material Suppliers – Biotech reagents, APIs, and specialized compounds.
- Manufacturers – Global and regional producers of primary hyperoxaluria drugs.
- Distributors/Wholesalers – Pharmaceutical supply chains and hospital procurement networks.
- Healthcare Providers – Hospitals, clinics, and specialty nephrology centers.
- Patients – End users benefiting from advanced rare disease therapies.
Quick Recommendations for Stakeholders
- Manufacturers: Invest in RNAi and gene therapies to capture premium demand.
- Distributors: Strengthen partnerships with hospitals and rare disease centers in emerging markets.
- Investors: Focus on companies innovating in RNAi and cell-based therapies.
- Policy Makers: Support affordable access to rare disease drugs through healthcare reforms and orphan drug incentives.
- Healthcare Providers: Integrate advanced therapies into treatment protocols for improved patient outcomes.
Table of Contents
Global Primary Hyperoxaluria Drug Market Research Report 2026
1 Industry Overview of Primary Hyperoxaluria Drug
1.1 Definition and Specifications of Primary Hyperoxaluria Drug
1.1.1 Definition of Primary Hyperoxaluria Drug
1.1.2 Specifications of Primary Hyperoxaluria Drug
1.2 Classification of Primary Hyperoxaluria Drug
1.2.1 ALLN-230
1.2.2 DCR-PHXC
1.2.3 ALN-GO1
1.2.4 Others
1.3 Applications of Primary Hyperoxaluria Drug
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Others
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 Europe
1.4.3 China
1.4.4 Japan
1.4.5 Southeast Asia
1.4.6 India
2 Manufacturing Cost Structure Analysis of Primary Hyperoxaluria Drug
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Primary Hyperoxaluria Drug
2.3 Manufacturing Process Analysis of Primary Hyperoxaluria Drug
2.4 Industry Chain Structure of Primary Hyperoxaluria Drug
3 Technical Data and Manufacturing Plants Analysis of Primary Hyperoxaluria Drug
3.1 Capacity and Commercial Production Date of Global Primary Hyperoxaluria Drug Major Manufacturers
3.2 Manufacturing Plants Distribution of Global Primary Hyperoxaluria Drug Major Manufacturers
3.3 R&D Status and Technology Source of Global Primary Hyperoxaluria Drug Major Manufacturers
3.4 Raw Materials Sources Analysis of Global Primary Hyperoxaluria Drug Major Manufacturers
4 Global Primary Hyperoxaluria Drug Overall Market Overview
4.1 E Overall Market Analysis
4.2 Capacity Analysis
4.2.1 E Global Primary Hyperoxaluria Drug Capacity and Growth Rate Analysis
4.2.2 Primary Hyperoxaluria Drug Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 E Global Primary Hyperoxaluria Drug Sales and Growth Rate Analysis
4.3.2 Primary Hyperoxaluria Drug Sales Analysis (Company Segment)
4.4 Sales Price Analysis
4.4.1 E Global Primary Hyperoxaluria Drug Sales Price
4.4.2 Primary Hyperoxaluria Drug Sales Price Analysis (Company Segment)
5 Primary Hyperoxaluria Drug Regional Market Analysis
5.1 North America Primary Hyperoxaluria Drug Market Analysis
5.1.1 North America Primary Hyperoxaluria Drug Market Overview
5.1.2 North America E Primary Hyperoxaluria Drug Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America E Primary Hyperoxaluria Drug Sales Price Analysis
5.1.4 North America Primary Hyperoxaluria Drug Market Share Analysis
5.2 Europe Primary Hyperoxaluria Drug Market Analysis
5.2.1 Europe Primary Hyperoxaluria Drug Market Overview
5.2.2 Europe E Primary Hyperoxaluria Drug Local Supply, Import, Export, Local Consumption Analysis
5.2.3 Europe E Primary Hyperoxaluria Drug Sales Price Analysis
5.2.4 Europe Primary Hyperoxaluria Drug Market Share Analysis
5.3 China Primary Hyperoxaluria Drug Market Analysis
5.3.1 China Primary Hyperoxaluria Drug Market Overview
5.3.2 China E Primary Hyperoxaluria Drug Local Supply, Import, Export, Local Consumption Analysis
5.3.3 China E Primary Hyperoxaluria Drug Sales Price Analysis
5.3.4 China Primary Hyperoxaluria Drug Market Share Analysis
5.4 Japan Primary Hyperoxaluria Drug Market Analysis
5.4.1 Japan Primary Hyperoxaluria Drug Market Overview
5.4.2 Japan E Primary Hyperoxaluria Drug Local Supply, Import, Export, Local Consumption Analysis
5.4.3 Japan E Primary Hyperoxaluria Drug Sales Price Analysis
5.4.4 Japan Primary Hyperoxaluria Drug Market Share Analysis
5.5 Southeast Asia Primary Hyperoxaluria Drug Market Analysis
5.5.1 Southeast Asia Primary Hyperoxaluria Drug Market Overview
5.5.2 Southeast Asia E Primary Hyperoxaluria Drug Local Supply, Import, Export, Local Consumption Analysis
5.5.3 Southeast Asia E Primary Hyperoxaluria Drug Sales Price Analysis
5.5.4 Southeast Asia Primary Hyperoxaluria Drug Market Share Analysis
5.6 India Primary Hyperoxaluria Drug Market Analysis
5.6.1 India Primary Hyperoxaluria Drug Market Overview
5.6.2 India E Primary Hyperoxaluria Drug Local Supply, Import, Export, Local Consumption Analysis
5.6.3 India E Primary Hyperoxaluria Drug Sales Price Analysis
5.6.4 India Primary Hyperoxaluria Drug Market Share Analysis
6 Global E Primary Hyperoxaluria Drug Segment Market Analysis (by Type)
6.1 Global E Primary Hyperoxaluria Drug Sales by Type
6.2 Different Types of Primary Hyperoxaluria Drug Product Interview Price Analysis
6.3 Different Types of Primary Hyperoxaluria Drug Product Driving Factors Analysis
6.3.1 ALLN-230 Growth Driving Factor Analysis
6.3.2 DCR-PHXC Growth Driving Factor Analysis
6.3.3 ALN-GO1 Growth Driving Factor Analysis
6.3.4 Others Growth Driving Factor Analysis
7 Global E Primary Hyperoxaluria Drug Segment Market Analysis (by Application)
7.1 Global E Primary Hyperoxaluria Drug Consumption by Application
7.2 Different Application of Primary Hyperoxaluria Drug Product Interview Price Analysis
7.3 Different Application of Primary Hyperoxaluria Drug Product Driving Factors Analysis
7.3.1 Hospital of Primary Hyperoxaluria Drug Growth Driving Factor Analysis
7.3.2 Clinic of Primary Hyperoxaluria Drug Growth Driving Factor Analysis
7.3.3 Others of Primary Hyperoxaluria Drug Growth Driving Factor Analysis
8 Major Manufacturers Analysis of Primary Hyperoxaluria Drug
8.1 Allena Pharmaceuticals Inc
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.2.1 Product A
8.1.2.2 Product B
8.1.3 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.1.4 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Business Region Distribution Analysis
8.2 Alnylam Pharmaceuticals Inc
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.2.1 Product A
8.2.2.2 Product B
8.2.3 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Business Region Distribution Analysis
8.3 Dicerna Pharmaceuticals Inc
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.2.1 Product A
8.3.2.2 Product B
8.3.3 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Business Region Distribution Analysis
8.4 Intellia Therapeutics Inc
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.2.1 Product A
8.4.2.2 Product B
8.4.3 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Business Region Distribution Analysis
8.5 OxThera AB
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.2.1 Product A
8.5.2.2 Product B
8.5.3 OxThera AB Primary Hyperoxaluria Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4 OxThera AB Primary Hyperoxaluria Drug Business Region Distribution Analysis
9 Development Trend of Analysis of Primary Hyperoxaluria Drug Market
9.1 Global Primary Hyperoxaluria Drug Market Trend Analysis
9.1.1 Global Primary Hyperoxaluria Drug Market Size (Volume and Value) Forecast
9.1.2 Global Primary Hyperoxaluria Drug Sales Price Forecast
9.2 Primary Hyperoxaluria Drug Regional Market Trend
9.2.1 North America Primary Hyperoxaluria Drug Consumption Forecast
9.2.2 Europe Primary Hyperoxaluria Drug Consumption Forecast
9.2.3 China Primary Hyperoxaluria Drug Consumption Forecast
9.2.4 Japan Primary Hyperoxaluria Drug Consumption Forecast
9.2.5 Southeast Asia Primary Hyperoxaluria Drug Consumption Forecast
9.2.6 India Primary Hyperoxaluria Drug Consumption Forecast
9.3 Primary Hyperoxaluria Drug Market Trend (Product Type)
9.4 Primary Hyperoxaluria Drug Market Trend (Application)
10 Primary Hyperoxaluria Drug Marketing Type Analysis
10.1 Primary Hyperoxaluria Drug Regional Marketing Type Analysis
10.2 Primary Hyperoxaluria Drug International Trade Type Analysis
10.3 Traders or Distributors with Contact Information of Primary Hyperoxaluria Drug by Region
10.4 Primary Hyperoxaluria Drug Supply Chain Analysis
11 Consumers Analysis of Primary Hyperoxaluria Drug
11.1 Consumer 1 Analysis
11.2 Consumer 2 Analysis
11.3 Consumer 3 Analysis
11.4 Consumer 4 Analysis
12 Conclusion of the Global Primary Hyperoxaluria Drug Market Professional Survey Report
Methodology
Analyst Introduction
Data Source
List of Tables and Figures
Figure Picture of Primary Hyperoxaluria Drug
Table Product Specifications of Primary Hyperoxaluria Drug
Table Classification of Primary Hyperoxaluria Drug
Figure Global Production Market Share of Primary Hyperoxaluria Drug by Type in
Figure ALLN-230 Picture
Table Major Manufacturers of ALLN-230
Figure DCR-PHXC Picture
Table Major Manufacturers of DCR-PHXC
Figure ALN-GO1 Picture
Table Major Manufacturers of ALN-GO1
Figure Others Picture
Table Major Manufacturers of Others
Table Applications of Primary Hyperoxaluria Drug
Figure Global Consumption Volume Market Share of Primary Hyperoxaluria Drug by Application in
Figure Hospital Examples
Table Major Consumers in Hospital
Figure Clinic Examples
Table Major Consumers in Clinic
Figure Others Examples
Table Major Consumers in Others
Figure Market Share of Primary Hyperoxaluria Drug by Regions
Figure North America Primary Hyperoxaluria Drug Market Size (Million USD) (2013-2025)
Figure Europe Primary Hyperoxaluria Drug Market Size (Million USD) (2013-2025)
Figure China Primary Hyperoxaluria Drug Market Size (Million USD) (2013-2025)
Figure Japan Primary Hyperoxaluria Drug Market Size (Million USD) (2013-2025)
Figure Southeast Asia Primary Hyperoxaluria Drug Market Size (Million USD) (2013-2025)
Figure India Primary Hyperoxaluria Drug Market Size (Million USD) (2013-2025)
Table Primary Hyperoxaluria Drug Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Primary Hyperoxaluria Drug in
Figure Manufacturing Process Analysis of Primary Hyperoxaluria Drug
Figure Industry Chain Structure of Primary Hyperoxaluria Drug
Table Capacity and Commercial Production Date of Global Primary Hyperoxaluria Drug Major Manufacturers
Table Manufacturing Plants Distribution of Global Primary Hyperoxaluria Drug Major Manufacturers
Table R&D Status and Technology Source of Global Primary Hyperoxaluria Drug Major Manufacturers
Table Raw Materials Sources Analysis of Global Primary Hyperoxaluria Drug Major Manufacturers
Table Global Capacity, Sales , Price, Cost, Sales Revenue (M USD) and Gross Margin of Primary Hyperoxaluria Drug E
Figure Global E Primary Hyperoxaluria Drug Market Size (Volume) and Growth Rate
Figure Global E Primary Hyperoxaluria Drug Market Size (Value) and Growth Rate
Table E Global Primary Hyperoxaluria Drug Capacity and Growth Rate
Table Global Primary Hyperoxaluria Drug Capacity (K Pcs) List (Company Segment)
Table E Global Primary Hyperoxaluria Drug Sales (K Pcs) and Growth Rate
Table Global Primary Hyperoxaluria Drug Sales (K Pcs) List (Company Segment)
Table E Global Primary Hyperoxaluria Drug Sales Price (USD/Pcs)
Table Global Primary Hyperoxaluria Drug Sales Price (USD/Pcs) List (Company Segment)
Figure North America Capacity Overview
Table North America Supply, Import, Export and Consumption (K Pcs) of Primary Hyperoxaluria Drug E
Figure North America E Primary Hyperoxaluria Drug Sales Price (USD/Pcs)
Figure North America Primary Hyperoxaluria Drug Sales Market Share
Figure Europe Capacity Overview
Table Europe Supply, Import, Export and Consumption (K Pcs) of Primary Hyperoxaluria Drug E
Figure Europe E Primary Hyperoxaluria Drug Sales Price (USD/Pcs)
Figure Europe Primary Hyperoxaluria Drug Sales Market Share
Figure China Capacity Overview
Table China Supply, Import, Export and Consumption (K Pcs) of Primary Hyperoxaluria Drug E
Figure China E Primary Hyperoxaluria Drug Sales Price (USD/Pcs)
Figure China Primary Hyperoxaluria Drug Sales Market Share
Figure Japan Capacity Overview
Table Japan Supply, Import, Export and Consumption (K Pcs) of Primary Hyperoxaluria Drug E
Figure Japan E Primary Hyperoxaluria Drug Sales Price (USD/Pcs)
Figure Japan Primary Hyperoxaluria Drug Sales Market Share
Figure Southeast Asia Capacity Overview
Table Southeast Asia Supply, Import, Export and Consumption (K Pcs) of Primary Hyperoxaluria Drug E
Figure Southeast Asia E Primary Hyperoxaluria Drug Sales Price (USD/Pcs)
Figure Southeast Asia Primary Hyperoxaluria Drug Sales Market Share
Figure India Capacity Overview
Table India Supply, Import, Export and Consumption (K Pcs) of Primary Hyperoxaluria Drug E
Figure India E Primary Hyperoxaluria Drug Sales Price (USD/Pcs)
Figure India Primary Hyperoxaluria Drug Sales Market Share
Table Global E Primary Hyperoxaluria Drug Sales (K Pcs) by Type
Table Different Types Primary Hyperoxaluria Drug Product Interview Price
Table Global E Primary Hyperoxaluria Drug Sales (K Pcs) by Application
Table Different Application Primary Hyperoxaluria Drug Product Interview Price
Table Allena Pharmaceuticals Inc Information List
Table Product Overview
Table Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Business Region Distribution
Table Alnylam Pharmaceuticals Inc Information List
Table Product Overview
Table Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Business Region Distribution
Table Dicerna Pharmaceuticals Inc Information List
Table Product Overview
Table Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Business Region Distribution
Table Intellia Therapeutics Inc Information List
Table Product Overview
Table Intellia Therapeutics Inc Primary Hyperoxaluria Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Intellia Therapeutics Inc Primary Hyperoxaluria Drug Business Region Distribution
Table OxThera AB Information List
Table Product Overview
Table OxThera AB Primary Hyperoxaluria Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure OxThera AB Primary Hyperoxaluria Drug Business Region Distribution
Figure Global Primary Hyperoxaluria Drug Market Size (K Pcs) and Growth Rate Forecast
Figure Global Primary Hyperoxaluria Drug Market Size (Million USD) and Growth Rate Forecast
Figure Global Primary Hyperoxaluria Drug Sales Price (USD/Pcs) Forecast
Figure North America Primary Hyperoxaluria Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure China Primary Hyperoxaluria Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Europe Primary Hyperoxaluria Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Southeast Asia Primary Hyperoxaluria Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Japan Primary Hyperoxaluria Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure India Primary Hyperoxaluria Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Table Global Sales Volume (K Pcs) of Primary Hyperoxaluria Drug by Type
Table Global Consumption Volume (K Pcs) of Primary Hyperoxaluria Drug by Application
Table Traders or Distributors with Contact Information of Primary Hyperoxaluria Drug by Region
Key Players
In addition to the listed manufacturers, the following companies are also significant participants in the global primary hyperoxaluria drug market:
- Pfizer Inc. (US)
- Novartis AG (Switzerland)
- Roche Holding AG (Switzerland)
- Eli Lilly and Company (US)
- Sanofi S.A. (France)
- Takeda Pharmaceutical Company Ltd. (Japan)
- Bristol Myers Squibb (US)
- Regeneron Pharmaceuticals, Inc. (US)
- Ultragenyx Pharmaceutical Inc. (US)
- Silence Therapeutics Plc (UK)
These players compete on innovation, clinical trial pipelines, regulatory approvals, and global distribution networks.
Segments Analysis
By Product Type
- ALLN-230 – Investigational therapy targeting oxalate metabolism.
- DCR-PHXC – RNAi-based therapy under development.
- ALN-GO1 – Alnylam’s siRNA therapy for primary hyperoxaluria.
- Others – Includes pipeline drugs, gene therapies, and supportive treatments.
By Application
- Hospitals – Primary centers for advanced rare disease treatment and clinical trials.
- Clinics – Outpatient facilities providing supportive therapies.
- Others – Includes academic research institutions and specialty nephrology centers.
Regional Analysis
- North America – Largest market, led by the U.S.; strong clinical trial activity and advanced rare disease infrastructure.
- Europe – Significant adoption in Germany, UK, and France; focus on EMA regulatory pathways and orphan drug incentives.
- Asia-Pacific – Fastest-growing region; China, India, and Japan drive growth due to rising healthcare investments and rare disease awareness.
- South America – Brazil and Argentina show increasing adoption in urban hospitals and specialty clinics.
- Middle East & Africa – Emerging demand in Saudi Arabia, Turkey, and South Africa, supported by expanding healthcare infrastructure.
